SKYRIZI

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Spain, Turkey, UK.

Active ingredients

The drug SKYRIZI contains one active pharmaceutical ingredient (API):

1	Risankizumab UNII 90ZX3Q3FR7 - RISANKIZUMAB
	Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds with high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine without binding to IL-12 and inhibits its interaction with the IL-23 receptor complex. IL-23 is a cytokine that is involved in inflammatory and immune responses. By blocking IL-23 from binding to its receptor, risankizumab inhibits IL-23-dependent cell signalling and release of proinflammatory cytokines.
	Read more about Risankizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SKYRIZI 90 mg / 180 mg / 360 mg Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)
SKYRIZI 600 mg Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)
SKYRIZI 75 mg / 150 mg Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AC18		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11827L, 11858D
BR	Câmara de Regulação do Mercado de Medicamentos	543719110004107
CA	Health Products and Food Branch	02487454
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	174-MBE-0121, 235-MBE-0822
EE	Ravimiamet	1794102, 1848416, 1848427, 1848438
ES	Centro de información online de medicamentos de la AEMPS	1191361001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	055240, 409325, 557887
FR	Base de données publique des médicaments	67060271
GB	Medicines & Healthcare Products Regulatory Agency	371219, 397916, 397922
HK	Department of Health Drug Office	66488
IL	מִשְׂרַד הַבְּרִיאוּת	9258, 9259, 9314, 9315
IT	Agenzia del Farmaco	047821018, 047821020, 047821032, 047821044, 047821057
JP	医薬品医療機器総合機構	3999450A1025, 3999450G1028, 3999450G2024, 3999450G3020, 3999450G4027
LT	Valstybinė vaistų kontrolės tarnyba	1087673, 1092291, 1092292
NL	Z-Index G-Standaard, PRK	197629
NZ	Medicines and Medical Devices Safety Authority	20126, 21860, 21949
PL	Rejestru Produktów Leczniczych	100417814, 100461473
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66053001, W67699001, W67700001, W69348001, W69349001
TR	İlaç ve Tıbbi Cihaz Kurumu	8680656080520, 8680656080599, 8680656080605
US	FDA, National Drug Code	0074-1050, 0074-1065, 0074-1066, 0074-1069, 0074-1070, 0074-2042, 0074-2100, 0074-5015, 0074-7032, 0074-7034, 0074-7036, 0074-7040, 0074-7042